Get the Stockscreener App
5.8021
0.26%
-0.0079
Sage Therapeutics Inc stock is traded at $5.8021, with a volume of 300.86K.
It is down -0.26% in the last 24 hours and down -12.73% over the past month.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
See More
Previous Close:
$5.81
Open:
$5.67
24h Volume:
300.86K
Relative Volume:
0.45
Market Cap:
$349.66M
Revenue:
$91.06M
Net Income/Loss:
$-503.14M
P/E Ratio:
-0.5849
EPS:
-9.92
Net Cash Flow:
$-424.74M
1W Performance:
-31.66%
1M Performance:
-12.73%
6M Performance:
-58.43%
1Y Performance:
-72.78%
1-Day Range:
$5.64
$5.89
1-Week Range:
$5.64
$7.965
52-Week Range:
$5.64
$28.26
Sage Therapeutics Inc Stock (SAGE) Company Profile
Name
Sage Therapeutics Inc
Sector
Industry
Phone
617-299-8380
Address
215 FIRST STREET, CAMBRIDGE, MA
Sage Therapeutics Inc Stock (SAGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-23 | Initiated | Deutsche Bank | Hold |
| Aug-08-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Aug-08-23 | Downgrade | Goldman | Buy → Neutral |
| Aug-08-23 | Downgrade | Needham | Buy → Hold |
| Aug-07-23 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-07-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-07-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-07-23 | Downgrade | Stifel | Buy → Hold |
| Aug-07-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Mar-13-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jan-03-23 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-01-22 | Initiated | Loop Capital | Hold |
| Mar-31-22 | Initiated | Berenberg | Hold |
| Nov-02-21 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-07-21 | Downgrade | Jefferies | Buy → Hold |
| Sep-23-21 | Initiated | Needham | Buy |
| Jun-16-21 | Downgrade | Citigroup | Buy → Neutral |
| Apr-07-21 | Initiated | Piper Sandler | Overweight |
| Feb-26-21 | Downgrade | Mizuho | Buy → Neutral |
| Feb-25-21 | Reiterated | H.C. Wainwright | Neutral |
| Feb-02-21 | Resumed | Raymond James | Mkt Perform |
| Jan-22-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-04-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-04-20 | Upgrade | Mizuho | Neutral → Buy |
| Dec-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-06-20 | Reiterated | H.C. Wainwright | Neutral |
| Sep-11-20 | Upgrade | Wedbush | Neutral → Outperform |
| Aug-10-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-08-20 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-08-20 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-18-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Feb-28-20 | Reiterated | H.C. Wainwright | Neutral |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-06-19 | Reiterated | RBC Capital Mkts | Outperform |
| Dec-05-19 | Reiterated | Guggenheim | Buy |
| Dec-05-19 | Downgrade | SunTrust | Buy → Hold |
| Oct-30-19 | Initiated | H.C. Wainwright | Neutral |
| May-23-19 | Initiated | Wedbush | Outperform |
| Apr-25-19 | Initiated | Jefferies | Buy |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Oct-11-18 | Initiated | Oppenheimer | Outperform |
View All
Sage Therapeutics Inc Stock (SAGE) Latest News
Sage Therapeutics' SWOT analysis: stock faces challenges amid CNS drug market shifts - Investing.com
Vanguard Group Inc's Recent Transaction in Sage Therapeutics Inc - GuruFocus.com
Objective long/short (SAGE) Report - Stock Traders Daily
SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GuruFocus.com
Shareholders that lost money on Sage Therapeutics, Inc.(SAGE) sh - GuruFocus.com
Class Action Filed Against Sage Therapeutics, Inc. (SAGE) Seekin - GuruFocus.com
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on B - GuruFocus.com
Pinnacle Associates Ltd. Has $1.22 Million Stock Position in Sage Therapeutics, Inc. (NASDAQ:SAGE) - MarketBeat
Sage Therapeutics Inc Sued for Securities Law ViolationsConta - GuruFocus.com
Sage Therapeutics Reports Q3 Growth and Strategic Focus - TipRanks
Sage Prioritizes Zurzuvae For PPD, Ends MDD Effort, Drops Zulresso - Citeline
SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit - GuruFocus.com
SAGE's Q3 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down - MSN
Sage Therapeutics CFO Kimi Iguchi resigns from position - XM
SAGE Therapeutics Announces Strategic Reorganization Amid Executive Departures - TipRanks
Cambridge biotech's layoffs will cut dozens of Mass. employees - The Business Journals
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
HC Wainwright Has Bearish Estimate for SAGE FY2024 Earnings - MarketBeat
What is HC Wainwright's Estimate for SAGE FY2028 Earnings? - MarketBeat
Sage Therapeutics, Inc. (NASDAQ:SAGE) Q3 2024 Earnings Call Transcript - Insider Monkey
Sage Therapeutics price target lowered to $26 from $52 at Piper Sandler - Yahoo Finance
Sage Therapeutics Inc (SAGE) Q3 2024 Earnings Call Highlights: S - GuruFocus.com
Biogen, Sage Therapeutics Drop Plans to Develop Partnered Drug in Major Depressive Disorder - MedCity News
Sage Therapeutics price target lowered to $14 from $25 at H.C. Wainwright - TipRanks
Scotiabank Lowers Sage Therapeutics (NASDAQ:SAGE) Price Target to $14.00 - MarketBeat
Sage Therapeutics price target lowered to $14 from $17 at Scotiabank - TipRanks
Sage Therapeutics' (SAGE) Overweight Rating Reiterated at Piper Sandler - MarketBeat
Sage Therapeutics Inc (SAGE) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... - Yahoo Finance
Sage to sunset first postpartum depression drug, focus on Zurzuvae - The Business Journals
Sage Therapeutics (NASDAQ:SAGE) Issues Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Sage Therapeutics, Inc. (SAGE) Reports Q3 Loss, Tops Revenue Estimates - MSN
Sage stock plunges 18% post-market following business update, earnings - MSN
Sage Therapeutics reports Q3 EPS ($1.53) , consensus ($1.53) - TipRanks
Sage Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Major Depressive Disorder Market Expected to Experience Major Growth by 2034, According to DelveInsight | Takeda, Otsuka Pharma, AbbVie, SAGE Therapeutics, Forest Laboratories, Axsome Therapeutics - The Globe and Mail
Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives $13.76 Average PT from Analysts - MarketBeat
Shareholders that lost money on Sage Therapeutics, Inc.(SAGE) should contact The Gross Law Firm about pending Class ActionSAGE - The Malaysian Reserve
Deadline on Oct. 28th coming up in Lawsuit for Investors who lost - openPR
SAGE SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
SAGE SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sage Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - GlobeNewswire Inc.
DEADLINE ALERT for OM, SAGE, and SMCI: The Law Offices of - GlobeNewswire
FINAL SAGE DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Sage Therapeutics, Inc. Investors to Join the Class Action Lawsuit! - AccessWire
Sage Therapeutics, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before October 28, 2024 to Discuss Your RightsSAGE - PR Newswire
FINAL REMINDER SAGE DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Sage Therapeutics, Inc. Investors to Participate in the Class Action Lawsuit! - AccessWire
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sage Therapeutics - Stockhouse Publishing
Sage Therapeutics (SAGE) Q2 Loss Wider Than Expected, Sales Rise - MSN
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sage Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesSAGE - PR Newswire
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Sage Therapeutics, Inc. (SAGE) - Business Wire
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sage Therapeutics - PR Newswire
Sage Therapeutics' SWOT analysis: biotech firm faces uphill battle with stock - Investing.com Australia
Layoffs hit Raleigh pharma company amid shakeup - The Business Journals
Sage Therapeutics Inc Stock (SAGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):